Cargando…
Pyrogallol-Phloroglucinol-6,6-Bieckolon Attenuates Vascular Smooth Muscle Cell Proliferation and Phenotype Switching in Hyperlipidemia through Modulation of Chemokine Receptor 5
Hyperlipidemia induces vascular smooth muscle cell (VSMC) proliferation and phenotype switching from contractile to synthetic. This process is involved in arterial remodeling via the chemokine ligand 5 (CCL5)/chemokine receptor 5 (CCR5) pathway. Arterial remodeling is related to atherosclerosis or i...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460451/ https://www.ncbi.nlm.nih.gov/pubmed/32727125 http://dx.doi.org/10.3390/md18080393 |
_version_ | 1783576604619833344 |
---|---|
author | Oh, Seyeon Son, Myeongjoo Park, Chul-Hyun Jang, Ji Tae Son, Kuk Hui Byun, Kyunghee |
author_facet | Oh, Seyeon Son, Myeongjoo Park, Chul-Hyun Jang, Ji Tae Son, Kuk Hui Byun, Kyunghee |
author_sort | Oh, Seyeon |
collection | PubMed |
description | Hyperlipidemia induces vascular smooth muscle cell (VSMC) proliferation and phenotype switching from contractile to synthetic. This process is involved in arterial remodeling via the chemokine ligand 5 (CCL5)/chemokine receptor 5 (CCR5) pathway. Arterial remodeling is related to atherosclerosis or intimal hyperplasia. The purpose of this study was to evaluate whether pyrogallol-phloroglucinol-6,6-bieckol (PPB) from E. cava reduces VSMC proliferation and phenotype switching via the CCL5/CCR5 pathway. The CCL5/CCR5 expression, VSMC proliferation and phenotypic alterations were evaluated using a cell model of VSMC exposed in hyperlipidemia, and an animal model of mice fed a high-fat-diet (HFD). The expression of CCL5/CCR5 increased in both the cell and animal models of hyperlipidemia. Treatment with PPB decreased CCL5/CCR5 expression in both models. The expression of contractile markers of VSMCs, including alpha-smooth muscle actin (α-SMA), smooth muscle myosin heavy chain (SM-MHC), and smooth muscle protein 22 alpha (SM22α), were decreased by hyperlipidemia and restored after treatment with PPB. The silencing of CCR5 attenuated the effects of PPB treatment. VSMC proliferation and the intima-media thickness of the aortas, increased with HFD and decreased after treatment with PPB. The VSMC proliferation ratio and messenger ribonucleic acid (mRNA) expression of cell cycle regulatory factors increased in the in vitro model and were restored after treatment with PPB. PPB treatment reduced VSMC proliferation and phenotype switching induced by hyperlipidemia through inhibition of the CCL5/CCR5 pathway. |
format | Online Article Text |
id | pubmed-7460451 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74604512020-09-03 Pyrogallol-Phloroglucinol-6,6-Bieckolon Attenuates Vascular Smooth Muscle Cell Proliferation and Phenotype Switching in Hyperlipidemia through Modulation of Chemokine Receptor 5 Oh, Seyeon Son, Myeongjoo Park, Chul-Hyun Jang, Ji Tae Son, Kuk Hui Byun, Kyunghee Mar Drugs Article Hyperlipidemia induces vascular smooth muscle cell (VSMC) proliferation and phenotype switching from contractile to synthetic. This process is involved in arterial remodeling via the chemokine ligand 5 (CCL5)/chemokine receptor 5 (CCR5) pathway. Arterial remodeling is related to atherosclerosis or intimal hyperplasia. The purpose of this study was to evaluate whether pyrogallol-phloroglucinol-6,6-bieckol (PPB) from E. cava reduces VSMC proliferation and phenotype switching via the CCL5/CCR5 pathway. The CCL5/CCR5 expression, VSMC proliferation and phenotypic alterations were evaluated using a cell model of VSMC exposed in hyperlipidemia, and an animal model of mice fed a high-fat-diet (HFD). The expression of CCL5/CCR5 increased in both the cell and animal models of hyperlipidemia. Treatment with PPB decreased CCL5/CCR5 expression in both models. The expression of contractile markers of VSMCs, including alpha-smooth muscle actin (α-SMA), smooth muscle myosin heavy chain (SM-MHC), and smooth muscle protein 22 alpha (SM22α), were decreased by hyperlipidemia and restored after treatment with PPB. The silencing of CCR5 attenuated the effects of PPB treatment. VSMC proliferation and the intima-media thickness of the aortas, increased with HFD and decreased after treatment with PPB. The VSMC proliferation ratio and messenger ribonucleic acid (mRNA) expression of cell cycle regulatory factors increased in the in vitro model and were restored after treatment with PPB. PPB treatment reduced VSMC proliferation and phenotype switching induced by hyperlipidemia through inhibition of the CCL5/CCR5 pathway. MDPI 2020-07-27 /pmc/articles/PMC7460451/ /pubmed/32727125 http://dx.doi.org/10.3390/md18080393 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Oh, Seyeon Son, Myeongjoo Park, Chul-Hyun Jang, Ji Tae Son, Kuk Hui Byun, Kyunghee Pyrogallol-Phloroglucinol-6,6-Bieckolon Attenuates Vascular Smooth Muscle Cell Proliferation and Phenotype Switching in Hyperlipidemia through Modulation of Chemokine Receptor 5 |
title | Pyrogallol-Phloroglucinol-6,6-Bieckolon Attenuates Vascular Smooth Muscle Cell Proliferation and Phenotype Switching in Hyperlipidemia through Modulation of Chemokine Receptor 5 |
title_full | Pyrogallol-Phloroglucinol-6,6-Bieckolon Attenuates Vascular Smooth Muscle Cell Proliferation and Phenotype Switching in Hyperlipidemia through Modulation of Chemokine Receptor 5 |
title_fullStr | Pyrogallol-Phloroglucinol-6,6-Bieckolon Attenuates Vascular Smooth Muscle Cell Proliferation and Phenotype Switching in Hyperlipidemia through Modulation of Chemokine Receptor 5 |
title_full_unstemmed | Pyrogallol-Phloroglucinol-6,6-Bieckolon Attenuates Vascular Smooth Muscle Cell Proliferation and Phenotype Switching in Hyperlipidemia through Modulation of Chemokine Receptor 5 |
title_short | Pyrogallol-Phloroglucinol-6,6-Bieckolon Attenuates Vascular Smooth Muscle Cell Proliferation and Phenotype Switching in Hyperlipidemia through Modulation of Chemokine Receptor 5 |
title_sort | pyrogallol-phloroglucinol-6,6-bieckolon attenuates vascular smooth muscle cell proliferation and phenotype switching in hyperlipidemia through modulation of chemokine receptor 5 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460451/ https://www.ncbi.nlm.nih.gov/pubmed/32727125 http://dx.doi.org/10.3390/md18080393 |
work_keys_str_mv | AT ohseyeon pyrogallolphloroglucinol66bieckolonattenuatesvascularsmoothmusclecellproliferationandphenotypeswitchinginhyperlipidemiathroughmodulationofchemokinereceptor5 AT sonmyeongjoo pyrogallolphloroglucinol66bieckolonattenuatesvascularsmoothmusclecellproliferationandphenotypeswitchinginhyperlipidemiathroughmodulationofchemokinereceptor5 AT parkchulhyun pyrogallolphloroglucinol66bieckolonattenuatesvascularsmoothmusclecellproliferationandphenotypeswitchinginhyperlipidemiathroughmodulationofchemokinereceptor5 AT jangjitae pyrogallolphloroglucinol66bieckolonattenuatesvascularsmoothmusclecellproliferationandphenotypeswitchinginhyperlipidemiathroughmodulationofchemokinereceptor5 AT sonkukhui pyrogallolphloroglucinol66bieckolonattenuatesvascularsmoothmusclecellproliferationandphenotypeswitchinginhyperlipidemiathroughmodulationofchemokinereceptor5 AT byunkyunghee pyrogallolphloroglucinol66bieckolonattenuatesvascularsmoothmusclecellproliferationandphenotypeswitchinginhyperlipidemiathroughmodulationofchemokinereceptor5 |